Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse
A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherap...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2023-01-01
|
| Series: | Tuberculosis and Respiratory Diseases |
| Subjects: | |
| Online Access: | http://e-trd.org/upload/pdf/trd-2022-0081.pdf |
| _version_ | 1797962698614374400 |
|---|---|
| author | Jeong Uk Lim |
| author_facet | Jeong Uk Lim |
| author_sort | Jeong Uk Lim |
| collection | DOAJ |
| description | A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), the landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained. |
| first_indexed | 2024-04-11T01:16:58Z |
| format | Article |
| id | doaj.art-1216a59e0ba043a4ba2486888a040826 |
| institution | Directory Open Access Journal |
| issn | 1738-3536 2005-6184 |
| language | English |
| last_indexed | 2024-04-11T01:16:58Z |
| publishDate | 2023-01-01 |
| publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
| record_format | Article |
| series | Tuberculosis and Respiratory Diseases |
| spelling | doaj.art-1216a59e0ba043a4ba2486888a0408262023-01-03T23:11:59ZengThe Korean Academy of Tuberculosis and Respiratory DiseasesTuberculosis and Respiratory Diseases1738-35362005-61842023-01-01861142210.4046/trd.2022.00814801Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative RelapseJeong Uk LimA significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a marginal increase in overall survival and a 15% decrease in relapse. With the advents of immunotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), the landscape of adjuvant treatment in completely resectable NSCLC is changing. Postoperative radiotherapy can be beneficial to patients who underwent surgical resection in certain clinical settings. In addition, new biomarkers that predict efficacy of EGFR TKI and immunotherapy as adjuvant treatment are also necessary. In this review, recent updates in adjuvant treatment in resectable NSCLC were briefly explained.http://e-trd.org/upload/pdf/trd-2022-0081.pdfcarcinoma, non-small-cell lungprotein kinase inhibitorschemotherapy, adjuvantrecurrencebiomarkers |
| spellingShingle | Jeong Uk Lim Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse Tuberculosis and Respiratory Diseases carcinoma, non-small-cell lung protein kinase inhibitors chemotherapy, adjuvant recurrence biomarkers |
| title | Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse |
| title_full | Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse |
| title_fullStr | Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse |
| title_full_unstemmed | Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse |
| title_short | Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse |
| title_sort | update on adjuvant treatment in resectable non small cell lung cancer and potential biomarkers predicting postoperative relapse |
| topic | carcinoma, non-small-cell lung protein kinase inhibitors chemotherapy, adjuvant recurrence biomarkers |
| url | http://e-trd.org/upload/pdf/trd-2022-0081.pdf |
| work_keys_str_mv | AT jeonguklim updateonadjuvanttreatmentinresectablenonsmallcelllungcancerandpotentialbiomarkerspredictingpostoperativerelapse |